<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05061069</url>
  </required_header>
  <id_info>
    <org_study_id>2018/0435</org_study_id>
    <secondary_id>T000917N</secondary_id>
    <nct_id>NCT05061069</nct_id>
  </id_info>
  <brief_title>Vestibular Infants Screening-Flanders</brief_title>
  <acronym>VIS-Flanders</acronym>
  <official_title>Implementation of a Standard Vestibular Screening Protocol for Hearing-impaired Infants in Flanders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Universit√© Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Fabiola Children's University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Turnhout</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gasthuis Zusters Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GZA Ziekenhuizen Campus Sint-Augustinus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jessa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Oost-Limburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Algemeen Stedelijk Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Algemeen Ziekenhuis Maria Middelares</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Delta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Lucas Brugge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eargroup</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sint-Lievenspoort Gent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CAR Stappie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hearing-impaired children are at risk for a vestibular impairment, as the auditory and&#xD;
      vestibular end organs are closely related. Although this can compromise a child's development&#xD;
      on many levels, vestibular testing is not routinely performed in this vulnerable group. This&#xD;
      project aims to give each congenitally hearing-impaired child in Flanders (Belgium) access to&#xD;
      a basic vestibular screening at a young age and set an example for other regions worldwide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The implementation of a vestibular screening in hearing-impaired babies of six months old&#xD;
      will timely discover vestibular problems to limit the impact on the (motor) development. The&#xD;
      cervical vestibular evoked myogenic potential (cVEMP) technique will be used as a vestibular&#xD;
      screening tool. Flanders is the first region worldwide that will implement a vestibular&#xD;
      screening. All official Flemish reference centres of Kind en Gezin (Child and Family) will&#xD;
      participate in this project.&#xD;
&#xD;
      Study purpose:&#xD;
&#xD;
      The final utilisation goal of this project is to limit the impact of a vestibular dysfunction&#xD;
      on the (motor) development of children. Since hearing-impaired children have a higher risk&#xD;
      for deficits of the vestibular (balance) organ, the researchers will focus on this vulnerable&#xD;
      group.&#xD;
&#xD;
      This will be accomplished by:&#xD;
&#xD;
        -  The implementation of a standard vestibular screening protocol in Flanders in&#xD;
           hearing-impaired children at the age of 6 months, enabling early diagnosis of vestibular&#xD;
           deficits and adequate referral for extensive vestibular testing, motor assessment and&#xD;
           rehabilitation.&#xD;
&#xD;
        -  Increasing the awareness for vestibular dysfunctions and its associated symptoms in&#xD;
           hearing-impaired children among parents, teachers, paramedics, specialists and other&#xD;
           social workers who are in close contact with hearing-impaired children. This should go&#xD;
           hand in hand with more effective patient care, because adequate therapy will start&#xD;
           sooner.&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      The aim of the project is to add a vestibular screening to the existing auditory screening&#xD;
      programme (MAICO test). The following steps will be performed to guarantee an accurate&#xD;
      vestibular follow-up in Flemish hearing-impaired children:&#xD;
&#xD;
        -  In case of a 'refer' on the second MAICO test, Kind en Gezin (Child and Family) will&#xD;
           refer the child to the reference centres of Kind en Gezin in Flanders.&#xD;
&#xD;
        -  These reference centres will perform a diagnostic hearing test (brainstem evoked&#xD;
           response audiometry: BERA) to confirm the permanent hearing loss (standard of care).&#xD;
&#xD;
        -  Each child with a confirmed hearing loss (BERA 'refer') will be subjected to a&#xD;
           vestibular screening at the age of six months (on average 120/year), combined with&#xD;
           tympanometry, in that specific reference centre at the age of six months. The cervical&#xD;
           vestibular evoked myogenic potential (cVEMP) technique will be used.&#xD;
&#xD;
        -  In case of a refer on the vestibular screening (cVEMP 'refer'), the reference centres&#xD;
           will refer the child for motor assessment and, if necessary, for rehabilitation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter non-commercial interventional academic research</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of hearing-impaired infants in Flanders with abnormal vestibular screening results.</measure>
    <time_frame>Each infants will be subjected to the screening at the age of six months. In case of inconclusive results during the first screening, the screening will be repeated within three months after the first screening moment.</time_frame>
    <description>The primary outcome measure is the number of hearing-impaired infants in Flanders with abnormal vestibular screening results according to the degree, laterality, and onset of hearing loss. Abnormality of the vestibular screening results is based on the rectified interpeak amplitude values of the cVEMP (cervical vestibular evoked myogenic potentials) responses.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Vestibular Disorder</condition>
  <condition>Hearing Impaired Children</condition>
  <arm_group>
    <arm_group_label>Infants with permanent hearing loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each infant with permanent hearing loss in Flanders will be offered a vestibular screening by means of the cVEMP (cervical vestibular evoked myogenic potentials) test to screen for vestibular deficits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>cervical vestibular evoked myogenic potentials (cVEMP)</intervention_name>
    <description>cVEMPs are ipsilateral, short latency, inhibitory myogenic potentials that assess otolith (mainly saccular) function and the integrity of the inferior branch of the vestibular nerve.</description>
    <arm_group_label>Infants with permanent hearing loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Flemish children with permanent congenital or delayed-onset hearing loss, which&#xD;
             occurred before the age of 9 months, are included.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with temporary hearing loss (e.g. due to otitis media) are excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leen Maes, Prof. Dr.</last_name>
    <role>Study Director</role>
    <affiliation>University Ghent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingeborg Dhooge, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <state>East-Flanders</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://VIS-Flanders.be/en/</url>
    <description>VIS-Flanders website for patients and health care workers</description>
  </link>
  <reference>
    <citation>Martens S, Dhooge I, Dhondt C, Leyssens L, Sucaet M, Vanaudenaerde S, Rombaut L, Maes L. Vestibular Infant Screening - Flanders: The implementation of a standard vestibular screening protocol for hearing-impaired children in Flanders. Int J Pediatr Otorhinolaryngol. 2019 May;120:196-201. doi: 10.1016/j.ijporl.2019.02.033. Epub 2019 Feb 25.</citation>
    <PMID>30849604</PMID>
  </reference>
  <results_reference>
    <citation>Martens S, Dhooge I, Dhondt C, Vanaudenaerde S, Sucaet M, Rombaut L, Boudewyns A, Desloovere C, Janssens de Varebeke S, Vinck AS, Vanspauwen R, Verschueren D, Foulon I, Staelens C, Van den Broeck K, De Valck C, Deggouj N, Lemkens N, Haverbeke L, De Bock M, √ñz O, Declau F, Devroede B, Verhoye C, Maes L. Vestibular Infant Screening (VIS)-Flanders: results after 1.5 years of vestibular screening in hearing-impaired children. Sci Rep. 2020 Dec 3;10(1):21011. doi: 10.1038/s41598-020-78049-z.</citation>
    <PMID>33273502</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vestibular</keyword>
  <keyword>balance</keyword>
  <keyword>hearing loss</keyword>
  <keyword>infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vestibular Diseases</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared as data related to health of patients is included.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

